Pricing Log in Create free account
Friday 6 November 2026 Export NTRA’s income statement to Excel — free account

Natera, Inc.

NTRA Healthcare Diagnostics & Research

Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.

Revenue
+34.1%
EPS
+34.4%
Free cash flow
−85.8%
Total debt
−0.06%

Quarter to September 2026, against a year earlier

316.48 47.28 −13.00%
Market cap
$52.4B
P/E
0.0×
Fwd P/E
−289×
Dividend yield
—
F-score
6/9
Altman Z
26.84
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Natera, Inc. 10-Q filed Aug 7, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 8:00 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 8, 2026: 18 added · 4 removed · 24 modified; 9 with only figures updated

  1. Modified · Overview

    During the threesix months ended March 31June 30, 2026, we processed approximately 1,013,6002,056,800 tests, comprised of approximately 999,2002,028,600 tests accessioned in our laboratory, compared to approximately 855,1001,708,200 tests processed, comprised of approximately 840,8001,680,100 tests accessioned in our laboratory, during the threesix months ended March 31June 30, 2025. This increase

45 more changes in this Item, word by word, in Powerpack.